Alvotech targets 50% U.S. Humira biosimilar market share by year-end as Q2 product revenues rise 77%
Source: SeekingAlpha
2025-08-14 11:39:39 ET
More on Alvotech
- Alvotech 2025 Q2 - Results - Earnings Call Presentation
- Alvotech (ALVO) Q2 2025 Earnings Call Transcript
- Alvotech: A Fast-Expanding Biosimilar Concern
- Alvotech Non-GAAP EPS of $0.49 beats by $0.49
- Alvotech names veteran Linda Jónsdóttir finance chief
Read the full article on Seeking Alpha
For further details see:
Alvotech targets 50% U.S. Humira biosimilar market share by year-end as Q2 product revenues rise 77%
Alvotech
NASDAQ: ALVO
ALVO Trading
-4.83% G/L:
$3.055 Last:
487,684 Volume:
$3.23 Open:
ALVO Latest News
May 11, 2026 04:30:00 am
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
ALVO Stock Data
$1,569,389,520
107,654,085
N/A
30
N/A
Pharmaceuticals
Healthcare
LU
Luxembourg
